{"id":53776,"date":"2023-02-09T05:02:40","date_gmt":"2023-02-09T04:02:40","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/tivic-health-systems-inc-announces-pricing-of-public-offering\/"},"modified":"2023-02-09T05:02:40","modified_gmt":"2023-02-09T04:02:40","slug":"tivic-health-systems-inc-announces-pricing-of-public-offering","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/tivic-health-systems-inc-announces-pricing-of-public-offering\/","title":{"rendered":"Tivic Health Systems, Inc. Announces Pricing of Public Offering"},"content":{"rendered":"
\n

SAN FRANCISCO–(BUSINESS WIRE)–$TIVC<\/a> #healthcare<\/a>—Tivic Health\u00ae Systems, Inc.<\/a> (\u201cTivic\u201d) (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced the pricing of an underwritten public offering of an aggregate of 20,000,000 shares of common stock. Each share is being sold to the public at a price of $0.25 per share, for aggregate gross proceeds of approximately $5,000,000, before deducting underwriting discounts and offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 3,000,000 shares of common stock to cover over-allotments at the public offering price, less the underwriting discount.\n<\/p>\n

<\/a><\/p>\n

\nThe Company intends to use the proceeds for the continued sales expansion of its first commercial product, ClearUP\u00ae, for sinus relief (including the penetration of healthcare professional networks), and clinical and regulatory costs for the expansion of existing and new product candidates. Although the Company, from time to time, evaluates potential strategic investments and acquisitions, it does not have any definitive agreements in place to make any such acquisitions at this current time.\n<\/p>\n

\nThe offering is expected to close on February 13, 2023, subject to satisfaction of customary closing conditions.\n<\/p>\n

\nThinkEquity is acting as sole book-running manager for the offering.\n<\/p>\n

\nA registration statement on Form S-1 (File No. 333-268010) relating to the shares was filed with the Securities and Exchange Commission (\u201cSEC\u201d) and became effective on February 8, 2023. This offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004, by telephone at (877) 436-3673, by email at prospectus@think-equity.com<\/a>. The final prospectus will be filed with the SEC and will be available on the SEC\u2019s website located at http:\/\/www.sec.gov<\/a>.\n<\/p>\n

\nThis press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.\n<\/p>\n

\nAbout Tivic<\/b>\n<\/p>\n

\nTivic Health Systems, Inc. is a commercial-phase health technology company delivering non-invasive bioelectronic treatments that provide consumers with a choice in the treatment of inflammation and certain other related conditions. For more information visit https:\/\/tivichealth.com<\/a> @TivicHealth.\n<\/p>\n

\nForward Looking Statements<\/b>\n<\/p>\n

\nThis press release contains \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d “will\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.\u2019s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the expected closing date of the offering and intended use of proceeds. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, such as the ability to consummate the offering and satisfy applicable closing conditions. These and other risks and uncertainties are described more fully in the section titled \u201cRisk Factors\u201d in the final prospectus related to the public offering filed with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required under applicable law.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contact:
\n
<\/b>Cheryl Delgreco
\n
Cheryl.Delgreco@tivichealth.com<\/a>
617-429-6749\n<\/p>\n

\nKayleigh Westerfield
\n
Kayleigh.Westerfield@tivichealth.com<\/a>
949-632-3439\n<\/p>\n

\nInvestor Contact:<\/b>
Hanover International, Inc.
\n
ir@tivichealth.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN FRANCISCO–(BUSINESS WIRE)–$TIVC #healthcare—Tivic Health\u00ae Systems, Inc. (\u201cTivic\u201d) (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced the pricing of an underwritten public offering of an aggregate of 20,000,000 shares of common stock. Each share is being sold to the public at a price of $0.25 per share, for … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53776","6":"format-standard","7":"category-industry"},"yoast_head":"\nTivic Health Systems, Inc. Announces Pricing of Public Offering - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/tivic-health-systems-inc-announces-pricing-of-public-offering\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tivic Health Systems, Inc. Announces Pricing of Public Offering - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SAN FRANCISCO–(BUSINESS WIRE)–$TIVC #healthcare—Tivic Health\u00ae Systems, Inc. (\u201cTivic\u201d) (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced the pricing of an underwritten public offering of an aggregate of 20,000,000 shares of common stock. Each share is being sold to the public at a price of $0.25 per share, for ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/tivic-health-systems-inc-announces-pricing-of-public-offering\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-09T04:02:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230208006051\/en\/1598992\/21\/Tivic_Health_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tivic-health-systems-inc-announces-pricing-of-public-offering\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tivic-health-systems-inc-announces-pricing-of-public-offering\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Tivic Health Systems, Inc. Announces Pricing of Public Offering\",\"datePublished\":\"2023-02-09T04:02:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tivic-health-systems-inc-announces-pricing-of-public-offering\\\/\"},\"wordCount\":645,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tivic-health-systems-inc-announces-pricing-of-public-offering\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230208006051\\\/en\\\/1598992\\\/21\\\/Tivic_Health_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tivic-health-systems-inc-announces-pricing-of-public-offering\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tivic-health-systems-inc-announces-pricing-of-public-offering\\\/\",\"name\":\"Tivic Health Systems, Inc. Announces Pricing of Public Offering - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tivic-health-systems-inc-announces-pricing-of-public-offering\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tivic-health-systems-inc-announces-pricing-of-public-offering\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230208006051\\\/en\\\/1598992\\\/21\\\/Tivic_Health_Logo.jpg\",\"datePublished\":\"2023-02-09T04:02:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tivic-health-systems-inc-announces-pricing-of-public-offering\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tivic-health-systems-inc-announces-pricing-of-public-offering\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tivic-health-systems-inc-announces-pricing-of-public-offering\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230208006051\\\/en\\\/1598992\\\/21\\\/Tivic_Health_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230208006051\\\/en\\\/1598992\\\/21\\\/Tivic_Health_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tivic-health-systems-inc-announces-pricing-of-public-offering\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tivic Health Systems, Inc. Announces Pricing of Public Offering\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tivic Health Systems, Inc. Announces Pricing of Public Offering - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/tivic-health-systems-inc-announces-pricing-of-public-offering\/","og_locale":"en_US","og_type":"article","og_title":"Tivic Health Systems, Inc. Announces Pricing of Public Offering - Pharma Trend","og_description":"SAN FRANCISCO–(BUSINESS WIRE)–$TIVC #healthcare—Tivic Health\u00ae Systems, Inc. (\u201cTivic\u201d) (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced the pricing of an underwritten public offering of an aggregate of 20,000,000 shares of common stock. Each share is being sold to the public at a price of $0.25 per share, for ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/tivic-health-systems-inc-announces-pricing-of-public-offering\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-09T04:02:40+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230208006051\/en\/1598992\/21\/Tivic_Health_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/tivic-health-systems-inc-announces-pricing-of-public-offering\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/tivic-health-systems-inc-announces-pricing-of-public-offering\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Tivic Health Systems, Inc. Announces Pricing of Public Offering","datePublished":"2023-02-09T04:02:40+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tivic-health-systems-inc-announces-pricing-of-public-offering\/"},"wordCount":645,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tivic-health-systems-inc-announces-pricing-of-public-offering\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230208006051\/en\/1598992\/21\/Tivic_Health_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/tivic-health-systems-inc-announces-pricing-of-public-offering\/","url":"https:\/\/pharma-trend.com\/en\/tivic-health-systems-inc-announces-pricing-of-public-offering\/","name":"Tivic Health Systems, Inc. Announces Pricing of Public Offering - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tivic-health-systems-inc-announces-pricing-of-public-offering\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tivic-health-systems-inc-announces-pricing-of-public-offering\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230208006051\/en\/1598992\/21\/Tivic_Health_Logo.jpg","datePublished":"2023-02-09T04:02:40+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/tivic-health-systems-inc-announces-pricing-of-public-offering\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/tivic-health-systems-inc-announces-pricing-of-public-offering\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/tivic-health-systems-inc-announces-pricing-of-public-offering\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230208006051\/en\/1598992\/21\/Tivic_Health_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230208006051\/en\/1598992\/21\/Tivic_Health_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/tivic-health-systems-inc-announces-pricing-of-public-offering\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Tivic Health Systems, Inc. Announces Pricing of Public Offering"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53776","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53776"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53776\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53776"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53776"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53776"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}